NCT06993454RecruitingNot Applicable
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
AdventHealth Translational Research Institute1 site in 1 country12 target enrollmentStarted: April 25, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Measurement of Endogenous Glucose Production (EGP)
Study Overview
Brief Summary
The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 25 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •for individuals with T2D and elevated liver fat ≥5.6%
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Male or (pre-menopausal) female, aged 25-55 years
- •Body mass index (BMI) between 25 and 45 kg/m2
- •Sedentary (1 day or less per week of structured exercise)
- •Type 2 diabetes mellitus: HbA1c ≥7.5%
- •Liver fat ≥5.6% based on MRI
- •Weight stable (± 2 kg) for prior 3 months
- •Inclusion criteria for lean, healthy controls
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Male or (pre-menopausal) female, aged 25-55 years
- •Body mass index (BMI) between 18.5 and 27.5 kg/m2
- •Normal liver fat (FibroScan CAP <249dB/m, <5.6% liver fat based on MRI)
- •Weight stable (± 2 kg) for prior 3 months
- •Active (≥3 day/week of structured exercise)
Exclusion Criteria
- •Exclusion criteria for individuals with T2D and elevated liver fat ≥5.6% Currently taking insulin, incretin mimetics, and/or thiazolidinediones
- •Any change in glucose-lowering medications within the previous three months.
- •Inability to stop any medications which interfere with glucose metabolism for visits 4 and
- •Resting blood pressure ≥ 160/100 mm Hg
- •Triglycerides ≥ 500 mg/dL
- •Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol
- •Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)
- •Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing
- •Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)
- •Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next 6 months
- •Post- or peri-menopausal women
- •Partial and/or full hysterectomy (self-report)
- •Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc
- •Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting
- •Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures
- •New onset (<3 months on a stable regime) hormone replacement therapy
- •Current use of beta-adrenergic blocking agents
- •Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months
- •Previous bariatric or other surgery for obesity
- •Abnormal blood count/anemia (hemoglobin <12 g/dl in men or 11 g/dl in women; Hct <34%), blood transfusion or blood donation within the last 2 months
- •Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products)
- •Current drug or alcohol abuse/dependence, or positive urine toxicology screen
- •Alcohol consumption >7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month)
- •Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening
- •Not physically capable of performing the exercise required of the study protocols
- •Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening.
- •Unable to tolerate MRI or claustrophobia.
- •Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year
- •Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy
- •Unable or unwilling to communicate with staff or to provide written informed consent
- •Exclusion criteria for lean, healthy controls
- •Currently taking insulin, injectable incretin mimetics, and/or thiazolidinediones
- •Taking glucose-lowering medications
- •HbA1c ≥ 5.7%; pre-diabetes, type 2 diabetes, or type 1 diabetes
- •Resting blood pressure ≥ 160/100 mm Hg
- •Triglycerides ≥ 500 mg/dL
- •Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol
- •Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)
- •Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing
- •Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)
- •Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next year
- •Post- or peri-menopausal women
- •Partial and/or full hysterectomy (self-report)
- •Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc
- •Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting
- •Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures
- •New onset (<3 months on a stable regime) hormone replacement therapy
- •Current use of beta-adrenergic blocking agents
- •Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months
- •Previous bariatric or other surgery for obesity
- +12 more not shown
Arms & Interventions
Lean, healthy controls
Other
Control group.
Intervention: Magnetic Resonance Liver Assessment (Other)
Lean, healthy controls
Other
Control group.
Intervention: Bike Exercise VO2max (Other)
Lean, healthy controls
Other
Control group.
Intervention: DEXA (Other)
Individuals with T2D and hepatic steatosis
Other
T2D group.
Intervention: Magnetic Resonance Liver Assessment (Other)
Individuals with T2D and hepatic steatosis
Other
T2D group.
Intervention: Bike Exercise VO2max (Other)
Individuals with T2D and hepatic steatosis
Other
T2D group.
Intervention: DEXA (Other)
Outcomes
Primary Outcomes
Measurement of Endogenous Glucose Production (EGP)
Time Frame: Day 14
Bulk EGP will be measured during resting and exercise conditions to determine how Endogenous Glucose Production (EGP) differs during exercise (compared to no exercise) in T2D and Metabolic dysfunction associated steatotic liver disease (MASLD).
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
The Acute Effect of Physical Activity on Blood Glucose in Pregnant WomenGestational DiabetesNCT03644238University of Aarhus15
Completed
Not Applicable
Effects of Physical Exercise on Blood Glucose and Pain From the Musculoskeletal System in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT02366416Nordsjaellands Hospital72
Unknown
Not Applicable
Effects of Aerobic Interval Training on Glucose Tolerance in Children and Adolescents With Cystic FibrosisCystic FibrosisNCT03653949Universidade Federal do Rio Grande do Norte20
Active, not recruiting
Not Applicable
Exercise-stimulated Muscle Glucose Uptake in Upper Body ObesityUpper Body ObesityNCT04532814Mayo Clinic48
Not yet recruiting
Not Applicable
Effects of exercise in controlling blood glucose in Type II Diabetes Mellitus patients.Diabetes Mellitus Type 2Metabolic and Endocrine - DiabetesACTRN12619000984190niversity of Tasmania48